These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 21591585)
21. Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study. Muzzey M; Tellor KB; Ramaswamy K; Schwarze M; Armbruster AL Ther Adv Cardiovasc Dis; 2020; 14():1753944720926824. PubMed ID: 32633682 [TBL] [Abstract][Full Text] [Related]
22. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. van Loon G; Blissitt KJ; Keen JA; Young LE Equine Vet J; 2004 Nov; 36(7):609-14. PubMed ID: 15581326 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E; Denjoy I Am J Cardiol; 1996 Jan; 77(3):66A-71A. PubMed ID: 8607394 [TBL] [Abstract][Full Text] [Related]
24. Convulsions after normal dose of lidocaine: a probable drug interaction. Landy C; Schaeffer E; Raynaud L; Favier JC; Plancade D Br J Anaesth; 2012 Apr; 108(4):701. PubMed ID: 22419631 [No Abstract] [Full Text] [Related]
25. The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Almroth H; Andersson T; Fengsrud E; Friberg L; Linde P; Rosenqvist M; Englund A J Intern Med; 2011 Sep; 270(3):281-90. PubMed ID: 21635583 [TBL] [Abstract][Full Text] [Related]
26. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. Taylor R; Gandhi MM; Lloyd G BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811 [TBL] [Abstract][Full Text] [Related]
27. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Zarembski DG; Nolan PE; Slack MK; Caruso AC Arch Intern Med; 1995 Sep; 155(17):1885-91. PubMed ID: 7677555 [TBL] [Abstract][Full Text] [Related]
28. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. Alboni P; Botto GL; Baldi N; Luzi M; Russo V; Gianfranchi L; Marchi P; Calzolari M; Solano A; Baroffio R; Gaggioli G N Engl J Med; 2004 Dec; 351(23):2384-91. PubMed ID: 15575054 [TBL] [Abstract][Full Text] [Related]
29. Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160 [TBL] [Abstract][Full Text] [Related]
30. Atrial fibrillation during pregnancy: cardioversion with flecainide. Lewis G; Currie P Br J Hosp Med (Lond); 2015 Dec; 76(12):720-1. PubMed ID: 26646336 [No Abstract] [Full Text] [Related]
32. Successful conversion of equine atrial fibrillation using oral flecainide. Risberg AI; McGuirk SM J Vet Intern Med; 2006; 20(1):207-9. PubMed ID: 16496944 [No Abstract] [Full Text] [Related]
33. Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation. Argall J; Crawford I Emerg Med J; 2004 Mar; 21(2):199. PubMed ID: 14988348 [TBL] [Abstract][Full Text] [Related]
34. [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room]. Antonelli D; Feldman A; Freedberg NA; Darawsha A; Rosenfeld T Harefuah; 2006 May; 145(5):342-4, 398. PubMed ID: 16805213 [TBL] [Abstract][Full Text] [Related]
35. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395 [TBL] [Abstract][Full Text] [Related]
36. Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Climent VE; Marin F; Mainar L; Gomez-Aldaravi R; Martinez JG; Chorro FJ; Roman P; Sogorb F Pacing Clin Electrophysiol; 2004 Mar; 27(3):368-72. PubMed ID: 15009866 [TBL] [Abstract][Full Text] [Related]
37. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Marcus FI Am J Cardiol; 1990 Aug; 66(3):366-7. PubMed ID: 2114783 [No Abstract] [Full Text] [Related]
38. Consequences of AV blockade omission in flecainide therapy. Ferrante JA; Rizvi M; Sakaan S; Eick J; Cutshall BT Nurse Pract; 2021 Jul; 46(7):10-13. PubMed ID: 34138806 [No Abstract] [Full Text] [Related]
39. An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial. Coyle JD; Schaal SF DICP; 1989 Jun; 23(6):478-9. PubMed ID: 2500783 [No Abstract] [Full Text] [Related]
40. Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation. Conde D; Costabel JP; Aragon M; Caro M; Ferro A; Klein A; Trivi M; Giniger A Can J Cardiol; 2013 Oct; 29(10):1330.e13. PubMed ID: 23465347 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]